Back to resultsEMDR in Adolescents With Bipolar Disorder and History of Trauma
Primary Purpose
Bipolar Disorder
Status
Unknown status
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Treatment as Usual
Sponsored by
About this trial
This is an interventional prevention trial for Bipolar Disorder
Eligibility Criteria
Inclusion Criteria:
- age between 12 and 17 years and 11 months;
- current clinical state of euthymia (patient stable or euthymic) after clinical evaluation, defined as the presence of clinical remission (CDRS ≤ 40, YMRS ≤ 12.5 and CGAS (Children's Global Assessment Scale) ≥ 51), being the presence of subsyndromic symptoms (YMRS> 8 and <14) admissible;
Presence of one or more distressing traumatic events, assessed by:
- Trauma subscale of the Post Traumatic Stress Disorder Questionnaire from the Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime Version (K-SADS-PL) , with frequency> 1;
- Holmes Rahes Stress Inventory for non-adults (H-RLSI) with frequency> 1;
- Children Revised Impact of Event Scale (CRIES)> 0;
- Childhood Trauma Questionnaire (CTQ)> 0; and
- at least 5 points in the disturbance assessment by the Subjective Units of Disturbance (SUDS) scale.
Exclusion Criteria:
- substance abuse / dependence within 3 months prior to participation;
- neurological disease or history of brain trauma;
- autism;
- Intelligence Quotient <70;
- suicidal or homicidal ideation;
- prior involvement in trauma-focused therapy;
- psychotherapy during the study and months of follow-up, and;
- a score greater than 25 on the Adolescent Dissociative Experience Scale, since the presence of massive dissociation requires different and more extensive treatment protocols.
Sites / Locations
- Centro de Pesquisas Clínicas do Hospital de Clínicas de Porto AlegreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
EMDR Therapy + TAU
TAU (Treatment as Usual)
Arm Description
Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU). It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life. Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma.
Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months. Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses.
Outcomes
Primary Outcome Measures
Reduction in the number of manic switches.
To verify if treatment with EMDR leads to a reduction in the number of manic episodes within a period of 12 months.This will be evaluated through the Young Mania Rating Scale (YMRS).
Reduction in the number of depressive episodes
To verify if treatment with EMDR leads to a reduction in the number of depressive episodes within a period of 12 months.This will be evaluated through the Children's Depression Rating Scale (CDRS).
Secondary Outcome Measures
Change in biological markers measured by morning salivary cortisol levels in 6 months
To analyze the biological markers related to BD, through the measurement of morning salivary cortisol levels.
Change in biological markers measured by morning salivary cortisol levels in 12 months
To analyze the biological markers related to BD, through the measurement of morning salivary cortisol levels.
Change in biological markers measured by C-reactive protein levels in 6 months.
To analyze the biological markers related to BD, through the measurement of C-reactive protein levels.
Change in biological markers measured by C-reactive protein levels in 12 months.
To analyze the biological markers related to BD, through the measurement of C-reactive protein levels.
Change in biological markers measured by Brain Derived Neurotrophic Factor levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Brain Derived Neurotrophic Factor levels.
Change in biological markers measured by Brain Derived Neurotrophic Factor levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Brain Derived Neurotrophic Factor levels.
Change in biological markers measured by Interleukin-1 Beta levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-1 Beta levels.
Change in biological markers measured by Interleukin-1 Beta levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-1 Beta levels.
Change in biological markers measured by Interleukin-2 levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-2 levels.
Change in biological markers measured by Interleukin-2 levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-2 levels.
Change in biological markers measured by Interleukin-4 levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-4 levels.
Change in biological markers measured by Interleukin-4 levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-4 levels.
Improvement in biological markers measured by Interleukin-6 levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-6 levels.
Change in biological markers measured by Interleukin-6 levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-6 levels.
Change in biological markers measured by Interleukin-10 levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-10 levels.
Change in biological markers measured by Interleukin-10 levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interleukin-10 levels.
Change in biological markers measured by Interferon-gamma levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Interferon-gamma levels.
Change in biological markers measured by Interferon-gamma levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Interferon-gamma levels.
Change in biological markers measured by Tumor Necrosis Factor alpha levels in 6 months.
To analyze the biological markers related to BD, through the measurement of Tumor Necrosis Factor alpha levels.
Change in biological markers measured by Tumor Necrosis Factor alpha levels in 12 months.
To analyze the biological markers related to BD, through the measurement of Tumor Necrosis Factor alpha levels.
Modification in neurocognitive functioning through the WASI test.
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Abbreviated Intelligence Scale (WASI).
Modification in neurocognitive functioning through the WISC-III test.
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Intelligence Scale for Children (WISC-III) in adolescents aged up to 17 years.
Modification in neurocognitive functioning through the WAIS-III test.
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Intelligence Scale for Adults - Third Edition (WAIS-III) for adolescents over 17 years of age.
Modification in neurocognitive functioning through the MAC Battery.
To verify if patients treated with EMDR will present an improvement in processing speed, access to semantic memory, and inhibitory control evaluated by means of the Verbal Fluency Tasks of the Montreal Communication Assessment Battery (MAC Battery).
Modification in neurocognitive functioning through the Hayling Test.
To verify if patients treated with EMDR will show an improvement in the signs of inattention, impulsivity (inhibitory failure), processing speed, semantic memory, language and cognitive flexibility through the Hayling Test.
Change in neurocognitive functioning through the MAC Battery Test.
To verify if patients treated with EMDR will present an improvement in short term memory, verbal work memory and inference processing through the Oral Narrative Discourse - MAC Battery test.
Change in neurocognitive functioning through the DNE test.
To verify if patients treated with EMDR will show an improvement in Reading Comprehension through the DNE (Discurso Narrativo Escrito or Written Narrative Speech) test.
Change in neurocognitive functioning through the NEUROPSILIN test.
Check if patients treated with EMDR will show an improvement in Sentence Writing (syntax) through the Spontaneous Sentence Writing Subtest - NEUPSILIN (Instrumento de Avaliação Neuropsicológica Breve Infantil or Child Brief Neuropsychological Assessment Instrument).
Change in neurocognitive functioning through the evaluation of Comprehension of Written language.
To verify if patients treated with EMDR will present an improvement in Comprehension of written language through the Subtest Comprehension Writing - NEUPSILIN.
Change in neurocognitive functioning through the evaluation of the Visuospatial Working Memory.
To verify if patients treated with EMDR will show an improvement in the Visuospatial Working Memory through the Visuospatial Working Memory Subtest - NEUPSILIN-INF.
Change in neurocognitive functioning through the Go-no-Go Subtest.
To verify if patients treated with EMDR will show an improvement in attention and inhibitory control through the Go-no-go Subtest - NEUPSILIN-INF.
Change in neurocognitive functioning through the Words Span in Sentences Subtest.
To verify if patients treated with EMDR will present an improvement in verbal work memory through the Words Span in Sentences Subtest.
Change in neurocognitive functioning through the Five Digit Test.
To verify if patients treated with EMDR will present an improvement in the automatic and controlled processes of attention, inhibitory control, impulsivity, self-monitoring, cognitive flexibility through the Five Digit Test.
Change in neurocognitive functioning through the Psychological Attention Battery.
To verify if patients treated with EMDR will show an improvement in the attention alternated, concentrated, and divided through the Psychological Attention Battery.
Change in neurocognitive functioning through the Test of School Performance.
To verify if patients treated with EMDR will present an improvement in the school performance in writing of words in reading, writing of isolated words and arithmetic through the Test of School Performance.
Full Information
NCT ID
NCT03946787
First Posted
April 17, 2019
Last Updated
May 10, 2019
Sponsor
Hospital de Clinicas de Porto Alegre
1. Study Identification
Unique Protocol Identification Number
NCT03946787
Brief Title
EMDR in Adolescents With Bipolar Disorder and History of Trauma
Official Title
EMDR Therapy in Relapse Prevention in Mood Episodes in Adolescents With Bipolar Disorder and History of Trauma: A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 5, 2019 (Actual)
Primary Completion Date
August 2019 (Anticipated)
Study Completion Date
January 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital de Clinicas de Porto Alegre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this research, EMDR protocol model specific for bipolar patients with a history of trauma, developed by Benedikt Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma will be adapted for adolescents. This protocol consists of a detailed survey of traumatic events, intervention and processing of these events according to the standard protocol developed by Shapiro.
The main hypothesis is that the use of EMDR in adolescents with BD and history of trauma, as a complement to the pharmacological treatment (Usual Treatment), would have beneficial effects in the course of the disease. Thus, the overall objective of this study is to examine whether EMDR therapy in adolescents with BD and history of traumatic events can reduce affective relapses within a 12-month period. In addition, improvement in biological markers related to BD is expected to be found when compared to the Usual Treatment. It is also expected that patients treated with EMDR will present a better neurocognitive functioning profile, assessed by means of a neuropsychological evaluation battery before and after the intervention, since recent studies show that the profile of humoral dysregulation, impulsiveness, difficulty in dealing with frustrations and social feedback in children and adolescents with BD is associated with poor cognitive control and executive function deficits.
Detailed Description
This will be a randomized controlled trial. Participants will be assigned to Eye Movement Desensitization and Reprocessing (EMDR) Therapy or Treatment as Usual (TAU) through block randomization. This process will be done using the program available at www. randomization.com.
In this study, EMDR Therapy will be applied in adolescents with BD and compared to the Usual Treatment. The neuropsychological profile of the patients will be evaluated before and after the interventions. In addition, the collection of the biological markers related to BD will be done by measuring the levels of salivary cortisol and serum levels of C-reactive protein (CRP), Brain Derived Neurotrophic Factor (BDNF), Interleukin (IL) - 1β, IL - 2, IL - 4, IL - 6, IL - 10, Interferon gamma (IFN-γ) and Tumor Necrosis Factor alpha(TNF-α) in these patients, since a study proposing the use of serological biomarkers for BD diagnosis concluded that the use of a single biomarker would be of little use and a combination of several biomarkers would be necessary.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Group A: Treatment as Usual (TAU);
Group B: TAU plus Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Masking
None (Open Label)
Allocation
Randomized
Enrollment
82 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EMDR Therapy + TAU
Arm Type
Active Comparator
Arm Description
Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).
It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.
Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma.
Arm Title
TAU (Treatment as Usual)
Arm Type
Placebo Comparator
Arm Description
Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.
Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses.
Intervention Type
Other
Intervention Name(s)
Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Other Intervention Name(s)
EMDR Therapy
Intervention Description
The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
Intervention Type
Other
Intervention Name(s)
Treatment as Usual
Other Intervention Name(s)
TAU
Intervention Description
TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
Primary Outcome Measure Information:
Title
Reduction in the number of manic switches.
Description
To verify if treatment with EMDR leads to a reduction in the number of manic episodes within a period of 12 months.This will be evaluated through the Young Mania Rating Scale (YMRS).
Time Frame
12 months
Title
Reduction in the number of depressive episodes
Description
To verify if treatment with EMDR leads to a reduction in the number of depressive episodes within a period of 12 months.This will be evaluated through the Children's Depression Rating Scale (CDRS).
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in biological markers measured by morning salivary cortisol levels in 6 months
Description
To analyze the biological markers related to BD, through the measurement of morning salivary cortisol levels.
Time Frame
6 months
Title
Change in biological markers measured by morning salivary cortisol levels in 12 months
Description
To analyze the biological markers related to BD, through the measurement of morning salivary cortisol levels.
Time Frame
12 months
Title
Change in biological markers measured by C-reactive protein levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of C-reactive protein levels.
Time Frame
6 months
Title
Change in biological markers measured by C-reactive protein levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of C-reactive protein levels.
Time Frame
12 months
Title
Change in biological markers measured by Brain Derived Neurotrophic Factor levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Brain Derived Neurotrophic Factor levels.
Time Frame
6 months
Title
Change in biological markers measured by Brain Derived Neurotrophic Factor levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Brain Derived Neurotrophic Factor levels.
Time Frame
12 months
Title
Change in biological markers measured by Interleukin-1 Beta levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-1 Beta levels.
Time Frame
6 months
Title
Change in biological markers measured by Interleukin-1 Beta levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-1 Beta levels.
Time Frame
12 months
Title
Change in biological markers measured by Interleukin-2 levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-2 levels.
Time Frame
6 months
Title
Change in biological markers measured by Interleukin-2 levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-2 levels.
Time Frame
12 months
Title
Change in biological markers measured by Interleukin-4 levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-4 levels.
Time Frame
6 months
Title
Change in biological markers measured by Interleukin-4 levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-4 levels.
Time Frame
12 months
Title
Improvement in biological markers measured by Interleukin-6 levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-6 levels.
Time Frame
6 months
Title
Change in biological markers measured by Interleukin-6 levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-6 levels.
Time Frame
12 months
Title
Change in biological markers measured by Interleukin-10 levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-10 levels.
Time Frame
6 months
Title
Change in biological markers measured by Interleukin-10 levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interleukin-10 levels.
Time Frame
12 months
Title
Change in biological markers measured by Interferon-gamma levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Interferon-gamma levels.
Time Frame
6 months
Title
Change in biological markers measured by Interferon-gamma levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Interferon-gamma levels.
Time Frame
12 months
Title
Change in biological markers measured by Tumor Necrosis Factor alpha levels in 6 months.
Description
To analyze the biological markers related to BD, through the measurement of Tumor Necrosis Factor alpha levels.
Time Frame
6 months
Title
Change in biological markers measured by Tumor Necrosis Factor alpha levels in 12 months.
Description
To analyze the biological markers related to BD, through the measurement of Tumor Necrosis Factor alpha levels.
Time Frame
12 months
Title
Modification in neurocognitive functioning through the WASI test.
Description
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Abbreviated Intelligence Scale (WASI).
Time Frame
12 months
Title
Modification in neurocognitive functioning through the WISC-III test.
Description
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Intelligence Scale for Children (WISC-III) in adolescents aged up to 17 years.
Time Frame
12 months
Title
Modification in neurocognitive functioning through the WAIS-III test.
Description
To verify if the patients treated with EMDR will present a better profile of neurocognitive functioning, evaluated by means of the Wechsler Intelligence Scale for Adults - Third Edition (WAIS-III) for adolescents over 17 years of age.
Time Frame
12 months
Title
Modification in neurocognitive functioning through the MAC Battery.
Description
To verify if patients treated with EMDR will present an improvement in processing speed, access to semantic memory, and inhibitory control evaluated by means of the Verbal Fluency Tasks of the Montreal Communication Assessment Battery (MAC Battery).
Time Frame
12 months
Title
Modification in neurocognitive functioning through the Hayling Test.
Description
To verify if patients treated with EMDR will show an improvement in the signs of inattention, impulsivity (inhibitory failure), processing speed, semantic memory, language and cognitive flexibility through the Hayling Test.
Time Frame
12 months
Title
Change in neurocognitive functioning through the MAC Battery Test.
Description
To verify if patients treated with EMDR will present an improvement in short term memory, verbal work memory and inference processing through the Oral Narrative Discourse - MAC Battery test.
Time Frame
12 months
Title
Change in neurocognitive functioning through the DNE test.
Description
To verify if patients treated with EMDR will show an improvement in Reading Comprehension through the DNE (Discurso Narrativo Escrito or Written Narrative Speech) test.
Time Frame
12 months
Title
Change in neurocognitive functioning through the NEUROPSILIN test.
Description
Check if patients treated with EMDR will show an improvement in Sentence Writing (syntax) through the Spontaneous Sentence Writing Subtest - NEUPSILIN (Instrumento de Avaliação Neuropsicológica Breve Infantil or Child Brief Neuropsychological Assessment Instrument).
Time Frame
12 months
Title
Change in neurocognitive functioning through the evaluation of Comprehension of Written language.
Description
To verify if patients treated with EMDR will present an improvement in Comprehension of written language through the Subtest Comprehension Writing - NEUPSILIN.
Time Frame
12 months
Title
Change in neurocognitive functioning through the evaluation of the Visuospatial Working Memory.
Description
To verify if patients treated with EMDR will show an improvement in the Visuospatial Working Memory through the Visuospatial Working Memory Subtest - NEUPSILIN-INF.
Time Frame
12 months
Title
Change in neurocognitive functioning through the Go-no-Go Subtest.
Description
To verify if patients treated with EMDR will show an improvement in attention and inhibitory control through the Go-no-go Subtest - NEUPSILIN-INF.
Time Frame
12 months
Title
Change in neurocognitive functioning through the Words Span in Sentences Subtest.
Description
To verify if patients treated with EMDR will present an improvement in verbal work memory through the Words Span in Sentences Subtest.
Time Frame
12 months
Title
Change in neurocognitive functioning through the Five Digit Test.
Description
To verify if patients treated with EMDR will present an improvement in the automatic and controlled processes of attention, inhibitory control, impulsivity, self-monitoring, cognitive flexibility through the Five Digit Test.
Time Frame
12 months
Title
Change in neurocognitive functioning through the Psychological Attention Battery.
Description
To verify if patients treated with EMDR will show an improvement in the attention alternated, concentrated, and divided through the Psychological Attention Battery.
Time Frame
12 months
Title
Change in neurocognitive functioning through the Test of School Performance.
Description
To verify if patients treated with EMDR will present an improvement in the school performance in writing of words in reading, writing of isolated words and arithmetic through the Test of School Performance.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age between 12 and 17 years and 11 months;
current clinical state of euthymia (patient stable or euthymic) after clinical evaluation, defined as the presence of clinical remission (CDRS ≤ 40, YMRS ≤ 12.5 and CGAS (Children's Global Assessment Scale) ≥ 51), being the presence of subsyndromic symptoms (YMRS> 8 and <14) admissible;
Presence of one or more distressing traumatic events, assessed by:
Trauma subscale of the Post Traumatic Stress Disorder Questionnaire from the Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime Version (K-SADS-PL) , with frequency> 1;
Holmes Rahes Stress Inventory for non-adults (H-RLSI) with frequency> 1;
Children Revised Impact of Event Scale (CRIES)> 0;
Childhood Trauma Questionnaire (CTQ)> 0; and
at least 5 points in the disturbance assessment by the Subjective Units of Disturbance (SUDS) scale.
Exclusion Criteria:
substance abuse / dependence within 3 months prior to participation;
neurological disease or history of brain trauma;
autism;
Intelligence Quotient <70;
suicidal or homicidal ideation;
prior involvement in trauma-focused therapy;
psychotherapy during the study and months of follow-up, and;
a score greater than 25 on the Adolescent Dissociative Experience Scale, since the presence of massive dissociation requires different and more extensive treatment protocols.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ives C Passos, PhD
Phone
+555133598845
Email
ivescp1@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tatiana L Peruzzolo
Phone
+555133598000
Email
tatiperuzzolo@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ives C Passos, PhD
Organizational Affiliation
Federal University of Health Science of Porto Alegre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro de Pesquisas Clínicas do Hospital de Clínicas de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035-007
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Rambo
Phone
+555133598943
Email
l-cpc-recepcao@hcpa.edu.br
First Name & Middle Initial & Last Name & Degree
Tatiana L Peruzzolo
Phone
+555133598943
Email
tperuzzolo_pos@hcpa.edu.br
First Name & Middle Initial & Last Name & Degree
Ives C Passos, PhD
First Name & Middle Initial & Last Name & Degree
Tatiana L Peruzzolo, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
EMDR in Adolescents With Bipolar Disorder and History of Trauma
We'll reach out to this number within 24 hrs